Photo by nci from unsplash
Significance Neuroendocrine prostate cancer (NEPC) is a highly aggressive variant of prostate cancer with few meaningful treatment options. As a result, patients have a poor prognosis once diagnosis is confirmed.… Click to show full abstract
Significance Neuroendocrine prostate cancer (NEPC) is a highly aggressive variant of prostate cancer with few meaningful treatment options. As a result, patients have a poor prognosis once diagnosis is confirmed. NEPC expresses a unique protein called delta-like ligand 3 (DLL3) on the cell surface that is absent on the cell surface of normal cells. Herein, we developed a molecularly targeted radiotherapeutic approach for NEPC treatment using anti-DLL3 antibody SC16 that is radiolabeled with the beta-emitting radioisotope lutetium-177 (177Lu). 177Lu-labeled SC16 demonstrated durable and complete responses in subcutaneous xenograft mouse models of NEPC, with a safe hematologic profile. These data will aid clinical translation and offer a unique avenue for treating NEPC.
Journal Title: Proceedings of the National Academy of Sciences of the United States of America
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!